Ceryvyn Therapeutics Limited CYVNY
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -100.00% | |||
| SG&A Expenses | 2.29% | -30.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 2.27% | -- | |||
| Total Operating Expenses | 2.29% | -26.86% | |||
| Operating Income | -2.29% | 26.85% | |||
| Income Before Tax | -2.29% | -103.03% | |||
| Income Tax Expenses | -2.26% | -579.38% | |||
| Earnings from Continuing Operations | -2.28% | -102.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.28% | -102.94% | |||
| EBIT | -2.29% | 26.85% | |||
| EBITDA | -2.29% | 26.87% | |||
| EPS Basic | -4.17% | -102.87% | |||
| Normalized Basic EPS | -6.67% | -102.86% | |||
| EPS Diluted | -4.17% | -102.87% | |||
| Normalized Diluted EPS | -6.67% | -102.86% | |||
| Average Basic Shares Outstanding | 0.00% | 2.71% | |||
| Average Diluted Shares Outstanding | 0.00% | 2.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||